Professor Joan S Brugge is a professor in the Department of Cell Biology at Harvard University and director of the Ludwig Center at the same university. The main research topic is the intracellular processes and signaling systems involved in tumorigenesis. Research on how oncogenes act in the early stages of the cancer process is also leading to the possibility of tumor surveillance. In addition, research on the mechanisms of response and resistance of cancer cells to drugs in breast cancer is being conducted, and several related important papers are being published. In this lecture, under the title of ‘Tumor heterogeneity and treatment resistance,’ important insights for tumor heterogeneity, one of the major mechanisms of drug resistance and strategies for overcoming drug resistance, will be explored.
Ladder of Cancer treatment : Precision medicine and Palliative care
Precision medicine and palliative care are two important pillars of modern cancer treatment. This session will cover the latest knowledge of immuno-oncology treatment as an adjuvant treatment and the direction of palliative care in each country.
In the Joint Symposium of the Korean Society for Radiation Oncology (KOSRO) and Korean Society of Medical Oncology (KSMO), the topic of the year is the “De-escalation and Escalation of Radiotherapy.” Breast cancers and HPV-positive head & neck cancers will be the subject of de-escalation radiotherapy, while the treatment of esophageal cancers and lung cancers will be discussed from the viewpoint of escalation radiotherapy.
Recent advances in Hepatocellular carcinoma/Pancreas-Biliary Ca
After the long stagnation in new drug development for hepatobiliary and pancreatic cancers, very encouraging clinical research results have recently been emerging. This session is anticipated to provide an opportunity to update the latest knowledge of hepatobiliary and pancreatic cancer through world-renowned leaders in the clinical research for these tumor types.
The activity of PARP inhibitors in BRCA1/2-deficient cancers is the archetype of synthetic lethality, but the indications of PARP inhibitors are expanding rapidly. Current clinical indications include ovarian, breast, prostate, and pancreas cancers with various biomarkers and diagnostic tools. This session highlights the characteristics of the tumors sensitive to PARP inhibitors and renowned experts will share their perspectives.
Multimodality Treatment Strategy: Primary surgery in de novo stage IV breast cancer, and neoadjuvant chemotherapy followed by surgery in locally advanced pancreatic cancer
A coordinated multidisciplinary approach is essential in the management of advanced cancer. In the KSSO/KSMO joint session, complicated issues in advanced breast and pancreatic cancer will be covered; surgical resection of the primary breast tumor in patients with stage IV breast cancer and neoadjuvant chemotherapy followed by surgery in locally advanced pancreatic cancer. Through this symposium, the perspectives from surgical and medical oncologists on each issue will be presented and shared for more successful treatment outcomes.
The KSP/KSMO Joint Symposium will focus on tumor microenvironments in pathology, which are considered to be important in cancer treatment and molecular diagnosis. We will introduce an example of AI-based biomarker development, multiplex immunohistochemistry, secretome analysis of extracellular space and spatial NGS for tumor microenvironments.
The relationship between infections and tumors has been actively studied in the past, but its importance has long been overlooked. In the so-called “era of immuno-oncology,” the relationship between infection and cancer is drawing attention again. This session will cover the impact of various bacterial and viral infections on cancers, tumor microenvironments, and immunotherapy - from preclinical to the latest clinical research findings.
This session is a joint symposium with the Korean Society of Radiology (KSR). This year, we will deal with state-of-the-art imaging techniques and imaging analysis methods for medical oncology. The audience will have an opportunity to know the recent advances in the oncology imaging field, which include "evolution of cancer imaging for response and toxicity assessment," "emerging response evaluation strategies on immunotherapy” and "molecular imaging for tumor immune microenvironment.”
Professor Jean-Charles SORIA is a professor of oncology at the University of Paris-Saclay University. He is the general director of the Institute Gustave Roussy Cancer Center and head of the Phase I clinical trial program. His main research subjects are lung cancer, phase 1 clinical trials, biomarker research, and precision medicine. From 2017 to 2019, he served as a senior vice-president of R&D at AstraZeneca, taking the lead in the development of immunotherapy and cell therapy drugs. As a lead researcher, he has published important papers in major journals while participating in research related to the development of immuno-oncology drugs and new anti-cancer targeted therapies. In this meeting, a plenary lecture titled ‘Drug development in oncology: The revolution of the last 15 years’ will be presented and address comprehensive research achievements so far, providing a direction for the future development of new drugs.